GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Total Inventories

Cadence Pharmaceuticals, (FRA:QEW) Total Inventories : €6.31 Mil (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Total Inventories?

Cadence Pharmaceuticals,'s total inventories for the quarter that ended in Dec. 2013 was €6.31 Mil. Cadence Pharmaceuticals,'s average total inventories from the quarter that ended in Sep. 2013 to the quarter that ended in Dec. 2013 was €5.44 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cadence Pharmaceuticals,'s Net-Net Working Capital per share for the quarter that ended in Dec. 2013 was €0.11.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cadence Pharmaceuticals,'s Days Inventory for the three months ended in Dec. 2013 was 58.83.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cadence Pharmaceuticals,'s Inventory Turnover for the quarter that ended in Dec. 2013 was 1.55.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cadence Pharmaceuticals,'s Inventory-to-Revenue for the quarter that ended in Dec. 2013 was 0.21.


Cadence Pharmaceuticals, Total Inventories Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Total Inventories Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.37 1.06 4.95 6.31

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 4.70 5.55 4.56 6.31

Cadence Pharmaceuticals, Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Cadence Pharmaceuticals,  (FRA:QEW) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cadence Pharmaceuticals,'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2013 is

Net-Net Working Capital Per Share (Q: Dec. 2013 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(41.903+0.75 * 6.789+0.5 * 6.312-40.825
-0-0)/86.7197
=0.11

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cadence Pharmaceuticals,'s Days Inventory for the three months ended in Dec. 2013 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2013 )/Cost of Goods Sold (Q: Dec. 2013 )*Days in Period
=5.435/8.43*365 / 4
=58.83

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cadence Pharmaceuticals,'s Inventory Turnover for the quarter that ended in Dec. 2013 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2013 ) / Average Total Inventories (Q: Dec. 2013 )
=8.43 / 5.435
=1.55

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cadence Pharmaceuticals,'s Inventory to Revenue for the quarter that ended in Dec. 2013 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2013 ) / Revenue (Q: Dec. 2013 )
=5.435 / 25.778
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Cadence Pharmaceuticals, Total Inventories Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines